Hurvitz SA - Search Results

1

Current approaches and future directions in the treatment of HER2-positive breast cancer.

Hurvitz SA, Hu Y, O'Brien N, Finn RS. Hurvitz SA, et al. Cancer Treat Rev. 2013 May;39(3):219-29. doi: 10.1016/j.ctrv.2012.04.008. Epub 2012 May 31. Cancer Treat Rev. 2013. PMID: 22658319 Free PMC article. Review.

2

Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.

Hurvitz SA, Pietras RJ. Hurvitz SA, et al. Cancer. 2008 Nov 1;113(9):2385-97. doi: 10.1002/cncr.23875. Cancer. 2008. PMID: 18819158 Free article. Review.

3

What's positive about 'triple-negative' breast cancer?

Hurvitz SA, Finn RS. Hurvitz SA, et al. Future Oncol. 2009 Sep;5(7):1015-25. doi: 10.2217/fon.09.68. Future Oncol. 2009. PMID: 19792970 Review.

4

A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).

Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. Hurvitz SA, et al. Clin Breast Cancer. 2010 Aug 1;10(4):307-12. doi: 10.3816/CBC.2010.n.040. Clin Breast Cancer. 2010. PMID: 20705564 Clinical Trial.

5

Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint.

Hurvitz SA. Hurvitz SA. Cancer Treat Rev. 2011 Nov;37(7):495-504. doi: 10.1016/j.ctrv.2011.01.002. Epub 2011 Feb 10. Cancer Treat Rev. 2011. PMID: 21315516 Free PMC article. Review.

6

Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.

Callahan R, Hurvitz S. Callahan R, et al. Curr Opin Obstet Gynecol. 2011 Feb;23(1):37-43. doi: 10.1097/gco.0b013e3283414e87. Curr Opin Obstet Gynecol. 2011. PMID: 21500375 Free PMC article. Review.

7

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.

8

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. Hurvitz SA, et al. Clin Cancer Res. 2012 Jun 15;18(12):3478-86. doi: 10.1158/1078-0432.CCR-11-2294. Epub 2012 Apr 13. Clin Cancer Res. 2012. PMID: 22504044 Free PMC article. Clinical Trial.

9

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA. Hurvitz SA, et al. J Clin Oncol. 2013 Mar 20;31(9):1157-63. doi: 10.1200/JCO.2012.44.9694. Epub 2013 Feb 4. J Clin Oncol. 2013. PMID: 23382472 Clinical Trial.

10

Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.

Peddi PF, Hurvitz SA. Peddi PF, et al. Among authors: hurvitz sa. Future Oncol. 2013 Mar;9(3):319-26. doi: 10.2217/fon.13.7. Future Oncol. 2013. PMID: 23469968 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page